O Brien Greene & Co. Inc reduced its stake in Johnson & Johnson (NYSE:JNJ) by 0.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,219 shares of the company’s stock after selling 120 shares during the period. Johnson & Johnson makes up approximately 2.8% of O Brien Greene & Co. Inc’s investment portfolio, making the stock its 11th biggest position. O Brien Greene & Co. Inc’s holdings in Johnson & Johnson were worth $4,224,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of JNJ. Exchange Traded Concepts LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $31,000. University of Texas Texas AM Investment Managment Co. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $31,000. Advocacy Wealth Management Services LLC boosted its stake in shares of Johnson & Johnson by 38.2% in the first quarter. Advocacy Wealth Management Services LLC now owns 300 shares of the company’s stock valued at $39,000 after buying an additional 83 shares during the period. Lion Street Advisors LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $45,000. Finally, Joseph P. Lucia & Associates LLC boosted its stake in shares of Johnson & Johnson by 50.8% in the first quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock valued at $49,000 after buying an additional 126 shares during the period. Institutional investors and hedge funds own 67.66% of the company’s stock.

NYSE JNJ opened at $144.37 on Friday. The company has a market capitalization of $386.52 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 3.19 and a beta of 0.71. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The stock has a fifty day simple moving average of $146.81 and a 200 day simple moving average of $142.30. The company has a quick ratio of 1.05, a current ratio of 1.31 and a debt-to-equity ratio of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.27. The business had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. Johnson & Johnson’s quarterly revenue was up 3.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.10 earnings per share. Research analysts expect that Johnson & Johnson will post 7.68 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a yield of 2.80%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date is Friday, May 22nd. Johnson & Johnson’s dividend payout ratio is presently 43.78%.

In related news, Director William D. Perez acquired 500 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the completion of the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.27% of the company’s stock.

Several brokerages recently issued reports on JNJ. Raymond James boosted their price target on Johnson & Johnson from $153.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Wells Fargo & Co upgraded Johnson & Johnson to a “hold” rating in a research note on Wednesday, April 22nd. Morgan Stanley upped their target price on Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Citigroup upped their target price on Johnson & Johnson from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $168.00 target price on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $163.47.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Initial Coin Offerings entail a high degree of risk

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.